Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Recurrence 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Dendritic Cell Sarcoma, Interdigitating 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 23fludarabine phosphate 20Cyclosporine 19Busulfan 17Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Antilymphocyte Serum 13Whole-Body Irradiation 12Radiotherapy 11Cord Blood Stem Cell Transplantation 10Methotrexate 9Filgrastim 9Methylprednisolone 8Cytarabine 6sargramostim 5Tacrolimus 5Melphalan 5Etoposide 5Cyclosporins 4merphos 3fludarabine 3Transplantation 3Thiotepa 3Granulocyte Colony-Stimulating Factor 3Decitabine 3bryostatin 1 2aldesleukin 2Topotecan 2Thioguanine 2Thalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory × hydrocortisone hemisuccinate × Clear all
NCT00003593 2013-06-27

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Children's Oncology Group

Phase 3 Completed
254 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡